Novartis intends to retain and transform its Sandoz generics and biosimilars business, a group spokesperson has told Generics bulletin, in response to rumours in a Swiss newspaper that the firm was looking to spin off its Sandoz division in its entirety.
“We are fully committed to Sandoz,” spokesperson Sreejit Mohan insisted. “Novartis is working to give Sandoz more freedom to operate...




